Investor desk
Investors should track partnership announcements, pipeline prioritization signals, and vendor consolidation themes emerging from ASCO 2026.
← Back to Events
Tier 1 Global Networking: High ONCOLOGY CONCLUDED
ASCO 2026 — McCormick Place, Chicago, United States
The 2026 ASCO Annual Meeting is The Place to Be. Learn more about the sessions, speakers, and science that will be presented at this year's meeting below. Answer who/what/when/where for ASCO 2026 Program pdf with verified dates, location, and what B2B readers should watch. ASCO 2
45,000+ Attendees
9 Presentations
7 Companies
7 Drugs
Presentation data updated Jun 5, 2026, 9:21 AM UTC
Why This Event Matters
The 2026 ASCO Annual Meeting is The Place to Be.
Industry impact
The 2026 ASCO Annual Meeting is The Place to Be.
Market implications
Expect signals on pricing, formulary strategy, and partnership economics relevant to oncology markets in the US region.
Regulatory implications
Trial readouts and FDA/EMA label-expansion discussions drive near-term catalysts for oncology investors attending this congress.
Investor implications
Investors should track partnership announcements, pipeline prioritization signals, and vendor consolidation themes emerging from ASCO 2026.
Competitive implications
Competitive positioning among top oncology players and adjacent technology vendors is a core theme — compare outcomes with prior editions and peer conferences.
Event Significance
Tier-1 industry catalyst
59 /100 composite
ASCO 2026 is a targeted oncology forum where specialty pipeline readouts and BD conversations drive near-term positioning decisions. Primary driver: speaker calibre and KOL density.
- Media coverage 10/20
Moderate coverage; Nova editorial will prioritize confirmed data releases.
- Speaker quality 20/20
Plenary and late-breaker slots attract global KOLs — high signal for clinical and regulatory teams.
- Pipeline relevance 2/20
Early science or services-focused — lower near-term PDUFA linkage.
- Historical influence 13/20
Some historical catalysts; compare readouts against last cycle.
- Company participation 14/20
Broad Big Pharma and biotech presence — competitive intelligence teams should map booth + poster overlap.
Nova Pharma Intelligence · Analyst desk
Key Takeaways
- Watch oral (Amgen · sotorasib): Phase III RASolute 303 trial of sotorasib in first-line KRAS G12C-mutated non-small cell lung cancer: early response rat…
- Watch late-breaker (Merck & Co. · pembrolizumab): Updated overall survival data from the Phase III KEYNOTE-789 trial of pembrolizumab in non-small cell lung cancer
- Watch oral (Gilead Sciences · sacituzumab tirumotecan): Phase III data of sacituzumab tirumotecan in triple-negative breast cancer
- Gilead Sciences carries 1 tracked presentations — map against peer readouts at ASCO 2026.
- Amgen carries 1 tracked presentations — map against peer readouts at ASCO 2026.
- pembrolizumab (Merck & Co.) — 1 data points on the schedule.
Timeline & Milestones
- Pre-event intelligence Complete
9 presentations tracked — Key Data and Companies hubs live.
- Conference opens Jun 5, 2026 Complete
Live readouts, late-breakers, and partnership announcements.
- Live coverage window Complete
1 Nova articles linked — see Coverage & Analysis.
- Conference closes Jun 9, 2026 Complete
Post-event recap, competitive takeaways, and trial updates.
Oncology BD teams Clinical development leaders Investors & analysts
Executive Summary
C-level briefThe 2026 ASCO Annual Meeting is The Place to Be.
Primary audience: Oncology BD teams · Clinical development leaders · Investors & analysts
Analyst Watch
Regulatory affairs
Trial readouts and FDA/EMA label-expansion discussions drive near-term catalysts for oncology investors attending this congress.
Competitive intelligence
Competitive positioning among top oncology players and adjacent technology vendors is a core theme — compare outcomes with prior editions and peer conferences.
vs. Prior Editions
| Edition | Presentations | Companies |
|---|---|---|
| ASCO 2026 (current) | 9 | 7 |
| ASCO (2026) | 5 | 0 |
| AACR/ASCO Methods in Clinical (2026) | 0 | 0 |
Most Anticipated Presentations
Full data hub → ORAL Jun 5
Phase III RASolute 303 trial of sotorasib in first-line KRAS G12C-mutated non-small cell lung cancer: early response rate data
LATE-BREAKER Jun 7
Updated overall survival data from the Phase III KEYNOTE-789 trial of pembrolizumab in non-small cell lung cancer
ORAL Jun 8
Phase III data of sacituzumab tirumotecan in triple-negative breast cancer
ORAL Jun 5
Updated results from the open-label Phase I/Ib CHRYSALIS-2 study (NCT04077463) of amivantamab and lazertinib in non-small cell lung cancer
POSTER Jun 6
Phase II data of pumitamig in relapsed/refractory multiple myeloma
Competitive Landscape
Company map →Competitive positioning among top oncology players and adjacent technology vendors is a core theme — compare outcomes with prior editions and peer conferences.
Companies to Watch
All companies →Drug Pipelines to Watch
Pipeline data →Related Clinical Trials
1 NCT IDs- NCT04077463 Updated results from the open-label Phase I/Ib CHRYSALIS-2 study (NCT04077463) o
Coverage & Analysis
1 articlesRelated News & Research
Research hub →Event Intelligence Summary
Standalone summaries for ASCO 2026 — optimized for research and AI retrieval.
Executive Summary
The 2026 ASCO Annual Meeting is The Place to Be.
Analyst View
The 2026 ASCO Annual Meeting is The Place to Be.
Investor View
Investors should track partnership announcements, pipeline prioritization signals, and vendor consolidation themes emerging from ASCO 2026.
BD View
BD teams should prioritize networking with presenting companies and services vendors at ASCO 2026, focusing on oncology partnership and licensing opportunities.
Key Facts
- Event
- ASCO 2026
- Focus
- oncology
- Region
- US Americas
- Attendance
- 45,000+
Ask Nova AI
AI-assisted answers grounded in NovaPharmaNews intelligence
Answers use retrieved site intelligence plus AI synthesis. Verify critical decisions with primary sources.
Frequently Asked Questions
What is ASCO 2026?
ASCO 2026 is a oncology industry conference bringing together executives, clinical leaders, and investors to discuss pipeline, regulatory, and commercial strategy.
Who attends ASCO 2026?
Typical attendees include pharma executives, BD teams, investors, regulatory affairs professionals, and clinical operations leaders focused on oncology.
Why is ASCO 2026 important?
ASCO 2026 influences partnership timing, pipeline prioritization, and policy debates that affect oncology markets for the next 12–18 months.
When is ASCO 2026?
ASCO 2026 takes place on the scheduled dates.
Where is ASCO 2026 held?
ASCO 2026 is held in the listed venue.
How many attendees does ASCO 2026 attract?
ASCO 2026 typically draws 45,000+ attendees from across the oncology ecosystem.
What companies participate at ASCO 2026?
7+ companies present data or participate in programming at ASCO 2026, spanning large pharma, biotech, and services vendors.
What should investors watch at ASCO 2026?
Investors should track partnership announcements, pipeline readouts, M&A signals, and management commentary on oncology catalysts during and after ASCO 2026.
What BD opportunities exist at ASCO 2026?
BD teams use ASCO 2026 for licensing discussions, co-development talks, and vendor selection across oncology — especially in networking sessions and satellite meetings.
How does ASCO 2026 compare with other pharma conferences?
ASCO 2026 is a tier-1 global congress for oncology — compare speaker quality, company participation, and historical deal flow with peer events in the same therapeutic or commercial vertical.
How do I get NovaPharmaNews coverage of ASCO 2026?
NovaPharmaNews publishes pre-event briefs, live coverage, and post-event analysis for ASCO 2026. Subscribe to event alerts on this page for breaking updates.